Low-Sodium Xywav Leads Jazz Pharma’s Oxybate Revenues
During the second quarter, Jazz Pharmaceuticals registered a 39% year-over-year growth in net product sales of its low-sodium Xywav.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
